|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| 12345678910111213...9899» |
- | Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change, Combination therapy: Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (clinicaltrials.gov) - Nov 30, 2023
P1, N=2, Terminated, Sponsor: University of Nebraska
N=30 --> 2
- | Trial termination: HSL2012-06: Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery (clinicaltrials.gov) - Nov 22, 2023
P=N/A, N=50, Terminated, Sponsor: Hospital Sirio-Libanes
N=30 --> 2 Suspended --> Terminated; There was recruted subject
- | Phase classification, Metastases: Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) - Oct 10, 2023
P=N/A, N=9, Completed, Sponsor: University of Nebraska
Suspended --> Terminated; There was recruted subject Phase classification: P1 --> P=N/A
- | Enrollment change, Trial withdrawal: Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=0, Withdrawn, Sponsor: University of Nebraska
Phase classification: P1 --> P=N/A N=30 --> 0 | Terminated --> Withdrawn
- | Xcytrin (motexafin gadolinum) / AbbVie
Trial completion date, Trial primary completion date: ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) - Jul 7, 2023
P=N/A, N=440, Active, not recruiting, Sponsor: American College of Radiology Imaging Network
N=30 --> 0 | Terminated --> Withdrawn Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- ||||||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Trial termination, Combination therapy: DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) - Jun 13, 2023
P3, N=453, Terminated, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Completed --> Terminated; Sponsor decision not based on any new unexpected safety findings or efficacy observations.
- | ribavirin / Generic mfg., daclatasvir/sofosbuvir / Generic mfg.
Trial completion: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics (clinicaltrials.gov) - Apr 24, 2019
P4, N=39, Completed, Sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Completed --> Terminated; Sponsor decision not based on any new unexpected safety findings or efficacy observations. Active, not recruiting --> Completed
- | Trial completion, Combination therapy: Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement? (clinicaltrials.gov) - Apr 23, 2019
P=N/A, N=88, Completed, Sponsor: Fourth Military Medical University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | sirolimus / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Metastases: A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2019
P1, N=24, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=64 --> 24 | Trial completion date: Jul 2019 --> Jul 2018
- | Biomarker, Trial completion, Trial completion date, Trial primary completion date: Nonalcoholic Fatty Liver Disease in Taiwanese Children (clinicaltrials.gov) - Apr 21, 2019
P=N/A, N=614, Completed, Sponsor: Far Eastern Memorial Hospital
Active, not recruiting --> Completed | N=64 --> 24 | Trial completion date: Jul 2019 --> Jul 2018 Recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Enrollment change, Trial termination, Surgery: IOUS: Freehand Ultrasound Elasticity Imaging in Liver Surgery (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=15, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 N=40 --> 15 | Recruiting --> Terminated; low accrual
- | Enrollment change, Trial termination: CATCH: Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 20, 2019
P3, N=7, Terminated, Sponsor: Rennes University Hospital
N=40 --> 15 | Recruiting --> Terminated; low accrual N=140 --> 7 | Active, not recruiting --> Terminated; insufficient recruitment
- | JNJ-47910382 / J&J
Enrollment change, Trial termination: A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients (clinicaltrials.gov) - Apr 20, 2019
P1, N=8, Terminated, Sponsor: Janssen R&D Ireland
N=140 --> 7 | Active, not recruiting --> Terminated; insufficient recruitment N=18 --> 8 | Recruiting --> Terminated; Because of many competing trials using the same mechanism of action, but being further advanced in development
- | Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Development of a Novel Biomarker for Liver Fibrosis (clinicaltrials.gov) - Apr 17, 2019
P=N/A, N=25, Completed, Sponsor: University of California, Los Angeles
N=18 --> 8 | Recruiting --> Terminated; Because of many competing trials using the same mechanism of action, but being further advanced in development Recruiting --> Completed | N=125 --> 25 | Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Jan 2019
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=28, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=125 --> 25 | Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Jan 2019 Recruiting --> Completed | N=75 --> 28 | Trial completion date: Apr 2019 --> Jul 2018 | Trial primary completion date: Apr 2019 --> Jul 2018
- | Trial completion: Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC (clinicaltrials.gov) - Mar 6, 2019
P3, N=668, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed | N=75 --> 28 | Trial completion date: Apr 2019 --> Jul 2018 | Trial primary completion date: Apr 2019 --> Jul 2018 Recruiting --> Completed
- | Trial completion: Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 6, 2019
P3, N=812, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed Recruiting --> Completed
- || Odomzo (sonidegib) / Sun Pharma
Trial completion, Trial completion date, Metastases: LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis (clinicaltrials.gov) - Mar 5, 2019
P1, N=9, Completed, Sponsor: Jason K. Sicklick, M.D.
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Sep 2017
- | Trial completion, Trial primary completion date: SIMPLIFY: A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (clinicaltrials.gov) - Feb 27, 2019
P2, N=103, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Apr 2017
- ||| Lipotecan (TLC388) / Taiwan Liposome Company
Trial termination, Metastases: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 26, 2019
P2, N=29, Terminated, Sponsor: Taiwan Liposome Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Apr 2017 Completed --> Terminated; Current study design couldn't support futher development on this indication
- Trial completion date: To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure (clinicaltrials.gov) - Feb 19, 2019
P3, N=18, Terminated, Sponsor: Vital Therapies, Inc.
Completed --> Terminated; Current study design couldn't support futher development on this indication Trial completion date: Oct 2015 --> Sep 2018
- | sterile N-Acetylcysteine / Generic mfg., acetylcysteine solution / Generic mfg.
Trial completion, Trial completion date: NAC in TB DIH: A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis (clinicaltrials.gov) - Feb 19, 2019
P2/3, N=102, Completed, Sponsor: University of Cape Town
Trial completion date: Oct 2015 --> Sep 2018 Recruiting --> Completed | Trial completion date: Aug 2019 --> Feb 2019
- | Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children (clinicaltrials.gov) - Feb 16, 2019
P3, N=36, Completed, Sponsor: Kapiolani Medical Center For Women & Children
Recruiting --> Completed | Trial completion date: Aug 2019 --> Feb 2019 Recruiting --> Completed | N=10 --> 36 | Trial completion date: Aug 2025 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Nov 2018
- | midodrine hydrochloride / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure (clinicaltrials.gov) - Feb 16, 2019
P2, N=0, Withdrawn, Sponsor: Anna Cruceta
Recruiting --> Completed | N=10 --> 36 | Trial completion date: Aug 2025 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Nov 2018 N=15 --> 0 | Trial completion date: Aug 2016 --> Aug 2017 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2014 --> Jul 2017
- | Biomarker, Enrollment change, Trial termination: Protein Biomarker in Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=211, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=15 --> 0 | Trial completion date: Aug 2016 --> Aug 2017 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2014 --> Jul 2017 N=1050 --> 211 | Suspended --> Terminated; Loss of funding due to difficulty with recruitment and participant retention.
- ||| tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Trial primary completion date: EMRP36100N: Tenofovir in Chronic Hepatitis B With Mild ALT Elevation (clinicaltrials.gov) - Feb 12, 2019
P4, N=160, Completed, Sponsor: E-DA Hospital
N=1050 --> 211 | Suspended --> Terminated; Loss of funding due to difficulty with recruitment and participant retention. Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Nov 2018
- | Trial completion, Trial completion date, Trial primary completion date: ALB-BET: Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites (clinicaltrials.gov) - Feb 11, 2019
P=N/A, N=46, Completed, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Nov 2018 Recruiting --> Completed | Trial completion date: Dec 2019 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
- ||| folate-tubulysin (EC1456) / Novartis
Trial completion, Trial completion date, Metastases: Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 7, 2019
P1, N=93, Completed, Sponsor: Endocyte
Recruiting --> Completed | Trial completion date: Dec 2019 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018
- | Trial completion: Effect of Dietary Macronutrient Composition (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=24, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018 Active, not recruiting --> Completed
- | Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial completion: Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=15, Completed, Sponsor: Children's Medical Center Dallas
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), Varivax (varicella virus vaccine live) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Phase classification: Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (clinicaltrials.gov) - Feb 4, 2019
P4, N=1800, Completed, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed Phase classification: P3 --> P4
- | Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial completion date, Trial primary completion date: Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=15, Enrolling by invitation, Sponsor: Children's Medical Center Dallas
Phase classification: P3 --> P4 Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- ||||| Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion: Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV . (clinicaltrials.gov) - Jan 31, 2019
P3, N=107, Completed, Sponsor: Universidad de Valparaiso
Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Recruiting --> Completed
- Kanuma (sebelipase alfa) / AstraZeneca
Trial completion, Trial primary completion date: VITAL: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency (clinicaltrials.gov) - Jan 30, 2019
P2/3, N=9, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial completion, Trial completion date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jan 25, 2019
P4, N=132, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017
- Trial completion date: Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) (clinicaltrials.gov) - Jan 23, 2019
P2, N=8, Terminated, Sponsor: Vital Therapies, Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017 Trial completion date: Sep 2015 --> Sep 2018
- | Enrollment change, Trial withdrawal, Trial primary completion date: Hepatocyte Transplantation for Acute Decompensated Liver Failure (clinicaltrials.gov) - Jan 23, 2019
P1, N=0, Withdrawn, Sponsor: Ira Fox
Trial completion date: Sep 2015 --> Sep 2018 N=15 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Oct 2018 --> Jan 2019
- | TG 4040 / Transgene
Enrollment change: TG4040 in Patients With Chronic HCV (clinicaltrials.gov) - Jan 23, 2019
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=15 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Oct 2018 --> Jan 2019 N=85 --> 0
- | Trial completion: Cholic Acid for Hepatic Steatosis in Lipodystrophy (clinicaltrials.gov) - Jan 16, 2019
P2, N=18, Completed, Sponsor: University of Texas Southwestern Medical Center
N=85 --> 0 Active, not recruiting --> Completed
- | Trial termination: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial (clinicaltrials.gov) - Jan 11, 2019
P2/3, N=79, Terminated, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Completed --> Terminated; protocol violation
- | Enrollment change, Trial withdrawal: Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
Completed --> Terminated; protocol violation N=100 --> 0 | Suspended --> Withdrawn
- | sirolimus / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Treg Liver Study: Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients (clinicaltrials.gov) - Jan 10, 2019
P1/2, N=9, Completed, Sponsor: Guy's and St Thomas' NHS Foundation Trust
N=100 --> 0 | Suspended --> Withdrawn Recruiting --> Completed | N=26 --> 9 | Trial primary completion date: Jun 2019 --> Jan 2018
- veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=44, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=26 --> 9 | Trial primary completion date: Jun 2019 --> Jan 2018 Recruiting --> Terminated
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial (clinicaltrials.gov) - Dec 14, 2018
P2/3, N=79, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Terminated Recruiting --> Completed | N=262 --> 79 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> Sep 2018
- | paracetamol / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial completion, Enrollment change: A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=177, Completed, Sponsor: Northwestern University
Recruiting --> Completed | N=262 --> 79 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> Sep 2018 Active, not recruiting --> Completed | N=3000 --> 177
- | Trial completion date: The Physiology of Fatigue in Patients With Chronic Liver Disease (clinicaltrials.gov) - Nov 23, 2018
P=N/A, N=12, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed | N=3000 --> 177 Trial completion date: Sep 2015 --> Nov 2018
- | Trial completion: Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production (clinicaltrials.gov) - Nov 16, 2018
P=N/A, N=60, Completed, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Sep 2015 --> Nov 2018 Enrolling by invitation --> Completed
- | Trial completion, Trial completion date: EFIGRO: Effect of Exercise on Hepatic Fat in Overweight Children (clinicaltrials.gov) - Nov 16, 2018
P=N/A, N=115, Completed, Sponsor: Basque Country University
Enrolling by invitation --> Completed Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018
- | Trial completion, Trial completion date, Trial primary completion date: Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma (clinicaltrials.gov) - Nov 13, 2018
P=N/A, N=60, Completed, Sponsor: University of Lausanne Hospitals
Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 Recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Feb 2018
- | Trial termination: The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes (clinicaltrials.gov) - Nov 8, 2018
P=N/A, N=126, Terminated, Sponsor: University of Florida
Recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Feb 2018 Active, not recruiting --> Terminated; Expired with the IRB